Autoimmune hemolytic anemia

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In hematology, Autoimmune hemolytic anemia (AIHA) is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]

Classification

Diagnosis

Treatment

As of 2010, no randomized controlled trials were available.[6] Subsequent studies are below.

Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[7]

References